Astria Therapeutics, Inc. (ATXS) Financials
ATXS Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 254.7 million | 11.6 million |
| 2023-09-30 | 193.9 million | 9.4 million |
| 2023-06-30 | 207.1 million | 6.7 million |
| 2023-03-31 | 218.2 million | 6.9 million |
ATXS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | -30.3 million | 2.1 million |
| 2023-09-30 | -14.3 million | 1.7 million |
| 2023-06-30 | -10.7 million | 1.3 million |
| 2023-03-31 | -13.3 million | 1.2 million |
ATXS Net Income
No data available :(
ATXS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 246.7 million | - | 329000 |
| 2023-09-30 | 188.8 million | - | 488000 |
| 2023-06-30 | 203.0 million | - | 643000 |
| 2023-03-31 | 213.3 million | - | 794000 |
ATXS Shares Outstanding
ATXS Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 16000 | 11.7 million | 7.3 million | - |
| 2023-09-30 | 4000 | 13.3 million | 6.9 million | - |
| 2023-06-30 | - | 9.1 million | 6.0 million | - |
| 2023-03-31 | 5000 | 8.0 million | 5.5 million | - |
ATXS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | - | - |
| 2023-09-30 | - | - |
| 2023-06-30 | - | - |
| 2023-03-31 | - | - |
ATXS
Price: $9.55
52 week price:
Earnings Per Share: -2.42 USD
P/E Ratio: -7.08
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 121600
Market Capitalization: 593.5 million